Wilsons analyst Melissa Benson maintained a Buy rating on Mayne Pharma Group Limited (MAYNF – Research Report) on August 8 and set a price target of AUD0.32. The company’s shares closed last Wednesday at $0.24.
Benson covers the Healthcare sector, focusing on stocks such as Pro Medicus Limited, Immutep Ltd, and Mayne Pharma Group Limited. According to TipRanks, Benson has an average return of -5.4% and a 36.36% success rate on recommended stocks.
Currently, the analyst consensus on Mayne Pharma Group Limited is a Moderate Buy with an average price target of $0.22.
See the top stocks recommended by analysts >>
MAYNF market cap is currently $412.7M and has a P/E ratio of (7.31).
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment involves in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty brands segments includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment offers manufacturing and selling of branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.
Read More on MAYNF:
- Macquarie Keeps Their Buy Rating on Reliance Worldwide Corp. Ltd. (RLLWF)
- REA Group Ltd (RPGRF) Gets a Hold from Morgan Stanley
- Morgan Stanley Keeps Their Buy Rating on LiveRamp Holdings (RAMP)
- Diamond Offshore Reports Second Quarter 2022 Results and Announces $610 Million in New Contract Awards
- Brookline Capital Markets Sticks to Their Buy Rating for Oncternal Therapeutics (ONCT)